A preponderance of evidence from the FDA cVAD Study, Impella Quality Assurance Database and physician-initiated National Cardiogenic Shock Initiative support the recommendation that placing Impella 2.5 or Impella CP pre-PCI improves outcomes.
This course is specifically for Surgeons, Heart Failure and Interventional Cardiologists (Heart Team) that treat patients with cardiogenic shock with a primary focus on survival with native heart recovery.
Use this FDA-approved checklist to guide treatment decisions and determine if the Impella RP is right for your patients. IMP-574
This sheath enables reaccess to the artery for the duration of Impella support with up to an 0.035” guidewire. The additional sheath length may provide improved hemostasis for tissue tracks longer than 6cm.
Adoption of best practices improves survival for patients with Acute Myocardial Infarction and Cardiogenic Shock (AMICS) supported with Impella.
Dr. Michael P. Flaherty’s TCT 2018 presentation on Renal Effects of Impella support during Protected PCI.
The Impella 5.0 is approved for use in cardiogenic shock, and is proven to unload the left ventricle and support the systemic circulation.
For patients in post cardiotomy cardiogenic shock (PCCS), the Impella LD can assist in the efforts to successfully unload the left ventricle and separate from bypass while offering full systemic circulatory support.